Cargando…

Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod

BACKGROUND: The majority of multiple sclerosis [MS] patients treated with fingolimod fail to develop a protective level of IgG humoral and adaptive cellular immune responses following full BNT162b2 SARS-CoV-2 vaccination. OBJECTIVE: To compare the efficacy of the third COVID-19 vaccine dose in vacci...

Descripción completa

Detalles Bibliográficos
Autores principales:	Achiron, Anat, Mandel, Mathilda, Gurevich, Michael, Dreyer-Alster, Sapir, Magalashvili, David, Sonis, Polina, Dolev, Mark, Menascu, Shay, Harari, Gil, Flechter, Shlomo, Falb, Rina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8889521/ https://www.ncbi.nlm.nih.gov/pubmed/35235002 http://dx.doi.org/10.1007/s00415-022-11030-0

Ejemplares similares

Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
por: Achiron, Anat, et al.
Publicado: (2021)

Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
por: Achiron, Anat, et al.
Publicado: (2021)

Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study
por: Achiron, Anat, et al.
Publicado: (2021)

SARS‐CoV‐2 memory B and T cell profiles in mild COVID‐19 convalescent patients
por: Gurevich, Michael, et al.
Publicado: (2022)

COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose
por: Dreyer-Alster, Sapir, et al.
Publicado: (2022)

In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab
por: Achiron, Anat, et al.
Publicado: (2023)

COVID‐19 Alpha Variant (B.1.1.7): Humoral, memory B and T cells in COVID‐19 pediatric convalescents
por: Gurevich, Michael, et al.
Publicado: (2022)

SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects
por: Achiron, Anat, et al.
Publicado: (2021)

Intravenous immunoglobulin treatment during pregnancy and the post-partum period in women with multiple sclerosis: A prospective analysis
por: Menascu, Shay, et al.
Publicado: (2023)

COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021
por: Achiron, Anat, et al.
Publicado: (2021)

Clinical and transcriptional recovery profiles in pediatric and adult multiple sclerosis patients
por: Menascu, Shay, et al.
Publicado: (2020)

Longitudinal relationships between disability and gait characteristics in people with MS
por: Dreyer-Alster, Sapir, et al.
Publicado: (2022)

Targeted cognitive game training enhances cognitive performance in multiple sclerosis patients treated with interferon beta 1-a
por: Menascu, Shay, et al.
Publicado: (2021)

Humoral SARS-COV-2 IgG decay within 6 months in COVID-19 healthy vaccinees: The need for a booster vaccine dose?
por: Achiron, Anat, et al.
Publicado: (2021)

Motoric cognitive risk syndrome in people with multiple sclerosis: prevalence and correlations with disease-related factors
por: Dreyer-Alster, Sapir, et al.
Publicado: (2022)

Faster progression to multiple sclerosis disability is linked to neuronal pathways associated with neurodegeneration: An ethnicity study
por: Harari, Gil, et al.
Publicado: (2023)

Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis
por: Gurevich, Michael, et al.
Publicado: (2015)

The Design, Development, and Testing of a Virtual Reality Device for Upper Limb Training in People With Multiple Sclerosis: Single-Center Feasibility Study
por: Kalron, Alon, et al.
Publicado: (2022)

Physical activity behavior in people with multiple sclerosis during the COVID-19 pandemic in Israel: Results of an online survey
por: Kalron, Alon, et al.
Publicado: (2021)

Cytokine prediction of mortality in COVID19 patients
por: Mandel, Mathilda, et al.
Publicado: (2020)

Cognitive function in multiple sclerosis: A long-term look on the bright side
por: Harel, Yermi, et al.
Publicado: (2019)

Suppressed RNA-Polymerase 1 Pathway Is Associated with Benign Multiple Sclerosis
por: Achiron, Anat, et al.
Publicado: (2012)

Understanding Autoimmune Mechanisms in Multiple Sclerosis Using Gene Expression Microarrays: Treatment Effect and Cytokine-related Pathways
por: Achiron, A., et al.
Publicado: (2004)

Optical Coherence Tomography Is Associated With Cognitive Impairment in Multiple Sclerosis
por: Dreyer-Alster, Sapir, et al.
Publicado: (2022)

Modeling of Cognitive Impairment by Disease Duration in Multiple Sclerosis: A Cross-Sectional Study
por: Achiron, Anat, et al.
Publicado: (2013)

Potential role of indolelactate and butyrate in multiple sclerosis revealed by integrated microbiome-metabolome analysis
por: Levi, Izhak, et al.
Publicado: (2021)

A personalized, intense physical rehabilitation program improves walking in people with multiple sclerosis presenting with different levels of disability: a retrospective cohort
por: Kalron, Alon, et al.
Publicado: (2015)

Unique Gene Expression Patterns in Human T-cell Lines Generated from Multiple Sclerosis Patients by Stimulation with a Synthetic MOG Peptide
por: Mandel, Mathilda, et al.
Publicado: (2005)

RAM-589.555 favors neuroprotective and anti-inflammatory profile of CNS-resident glial cells in acute relapse EAE affected mice
por: Zilkha-Falb, Rina, et al.
Publicado: (2020)

No evidence for an association between alcohol consumption and Multiple Sclerosis risk: a UK Biobank study
por: Dreyer-Alster, Sapir, et al.
Publicado: (2022)

An Immersive Virtual Kitchen Training System for People with Multiple Sclerosis: A Development and Validation Study
por: Pau, Massimiliano, et al.
Publicado: (2023)

Molecular Profiling of Glatiramer Acetate Early Treatment Effects in Multiple Sclerosis
por: Achiron, Anat, et al.
Publicado: (2009)

Optimizing multiple sclerosis diagnosis: gene expression and genomic association
por: Gurevich, Michael, et al.
Publicado: (2015)

The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis
por: Vališ, Martin, et al.
Publicado: (2023)

Static Posturography and Falls According to Pyramidal, Sensory and Cerebellar Functional Systems in People with Multiple Sclerosis
por: Kalron, Alon, et al.
Publicado: (2016)

Effect of Fingolimod on Platelet Count Among Multiple Sclerosis Patients
por: Farrokhi, Mehrdad, et al.
Publicado: (2015)

Unique features of central neuropathic pain in multiple sclerosis: Results of a cluster analysis
por: Rivel, Michal, et al.
Publicado: (2022)

Prediction of acute multiple sclerosis relapses by transcription levels of peripheral blood cells
por: Gurevich, Michael, et al.
Publicado: (2009)

Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East
por: Achiron, Anat, et al.
Publicado: (2017)

The intercorrelations between blood levels of ferritin, sCD163, and IL-18 in COVID-19 patients and their association to prognosis
por: Volfovitch, Yuval, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cg7m337dhlqvertqc5qfei8s1l